Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences
between the two drugs. To determine and compare whether intraocular aflibercept and
ranibizumab decreases rubeosis iridis (RI) in patients with neovascular glaucoma (NVG).